Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | NMT2 | O60551 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26524137 | 0.96 | GLP1R (0.45) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL18715477 | 0.89 | GLP1R (0.47) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL18715474 | 0.89 | GLP1R (0.47) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL18708280 | 0.89 | GLP1R (0.53) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL18708278 | 0.88 | GLP1R (0.48) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL18715473 | 0.86 | GLP1R (0.46) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL26524141 | 0.85 | GLP1R (0.44) | GLP1RMEN1KMT2ALPAR3TLR2 | |
| SCHEMBL26524106 | 0.83 | GLP1R (0.47) | GLP1RLPAR3TLR2LPAR1TSHR | |
| SCHEMBL19320390 | 0.82 | GLP1R (0.58) | GLP1RLPAR3TLR2LPAR1 | |
| SCHEMBL20800966 | 0.82 | GLP1R (0.52) | GLP1RLPAR3TLR2LPAR1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20180195070-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.